Validation of the effectiveness of a self-sampling high-risk human papillomavirus (hrHPV) test through the Web: a prospective study using questionnaires in hrHPV-positive women on the possibility of motivating them to receive cervical cancer screening and its usefulness as a CIN 2 or worse detection tool
Not Applicable
Recruiting
- Conditions
- cervical cancer and cervical intraepithelial neoplasia
- Registration Number
- JPRN-UMIN000045183
- Lead Sponsor
- Eurofins GeneticLab Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 5000
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Women who do not consent to participate (2) Male (3) Women less than 20 years old (4) Women in pregnancy (5) Women who are judged inappropriate for the test by a doctor
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The detection rate of cervical intraepithelial neoplasia grade 2 (CIN 2) or worse during whole periods
- Secondary Outcome Measures
Name Time Method Application rate for self-sampling hrHPV test through the Web Frequency of self-sampling hrHPV testing Positive rate of hrHPV tests Invalid specimens rate for testing Questionnaire survey Frequency of receiving cervical cancer screening Frequency of receiving cytology Frequency of detailed examination required Frequency of receiving detailed examination Detection rate of CIN 2 or worse per cytology Frequency of adverse events